| |
Tenofovir alafenamide versus tenofovir disoproxil fumarate: is
there a true difference in efficacy and safety?
Hill A, Hughes SL, Gotham D, Pozniak AL.
J Virus Erad. 2018 Apr
1;4(2):72-79.
Abstract
Immunological
outcomes of Tenofovir versus Zidovudine-based regimens among people living with
HIV/AIDS: a two years retrospective cohort study.
Ayele T, Jarso H, Mamo
G.
AIDS Res Ther. 2017 Feb 1;14(1):5.
Abstract
Lipid-lowering effect and changes in estimated cardiovascular
risk after switching to a tenofovir-containing regimen for the treatment of
HIV-infected patients.
Gagliardini R, Fabbiani M, Colafigli M,
et al
J Chemother. 2016 Dec
26:1
Abstract
Lipid-lowering effect and changes in estimated cardiovascular
risk after switching to a tenofovir-containing regimen for the treatment of
HIV-infected patients.
Gagliardini R, Fabbiani M, Colafigli M,
et al
J Chemother. 2016 Dec 26
Abstract
Comparative effectiveness of tenofovir in HIV-infected
treatment-experienced patients: systematic review and meta-analysis.
Ewald H, Santini-Oliveira M, Bühler JE,
et al
HIV
Clin Trials. 2016 Dec 13:1-11.
Abstract
FULL-TEXT ARTICLE
The efficacy and
safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in
antiretroviral regimens for HIV-1 therapy: Meta-analysis.
Wang H, Lu X, Yang X,et al.
Medicine (Baltimore).
2016 Oct;95(41):e5146.
Paper
FULL-TEXT
ARTICLE
Long-Term
Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the
Co-Administration of Other Drug Classes in Routine Clinical Practice.
Costarelli S, Cozzi-Lepri A, Lapadula G, et
al
PLoS One.
2016 Oct 7;11(10):e0160761.
Paper
The effect of Tenofovir on renal function among Ugandan adults on long-term
antiretroviral therapy: a cross-sectional enrolment analysis.
Salome T, Kasamba I, Mayanja BN,
AIDS Res Ther.
2016 Aug 30;13(1):28.
Abstract
Renal outcomes after up to eight years of tenofovir exposure in
HIV-HBV-coinfected patients.
Boyd A, Miailhes P, Lascoux-Combe C,
Antivir Ther. 2016 Aug
24.
Abstract
FULL-TEXT ARTICLE
Is There a Need for Viral Load Testing to Assess Treatment Failure in
HIV-Infected Patients Who Are about to Change to Tenofovir-Based First-Line
Antiretroviral Therapy? Programmatic Findings from Myanmar.
Thiha N, Chinnakali P, Harries AD, et al
PLoS One. 2016 Aug
9;11(8):e0160616.
Paper
Optimizing the virological success of tenofovir
DF/FTC/rilpivirine in HIV-infected naive and virologically suppressed patients
through strict clinical and virological selection.
Bernaud C, Khatchatourian L, Rodallec A,
Infect D Infect Dis (Lond). 2016 Oct;48(10):754-9(Lond).
2016 Oct;48(10):754-9.
Abstract
Prevalence and significance of proximal renal
tubular abnormalities in HIV-infected patients receiving
tenofovir.
Casado JL, Bañón S, Santiuste C,
et al
AIDS. 2016
Jan;30(2):231-9. '
Abstract
Treatment options after virological failure of first-line tenofovir-based
regimens in South Africa: an analysis by deep sequencing.
Casadellà M, Noguera-Julian M, Sunpath H, et al
AIDS. 2016 Jan 23
Abstract
Prevalence of K65R in patients treated with tenofovir disoproxil fumarate:
recommendations based on the Frankfurt HIV Cohort Study Resistance Database (FHCS-RD).
Reinheimer C, Wesner A, Keppler OT,
et al
Med Microbiol Immunol. 2016
Jan 8.
Abstract
Tenofovir monotherapy after achieving complete viral suppression
on entecavir plus tenofovir combination therapy.
Kim LH, Chaung KT, Ha NB, et al
Eur J Gastroenterol Hepatol. 2015 Apr
21.
Abstract
FULL-TEXT ARTICLE
Week 120 Efficacy of Tenofovir, Lamivudine and Lopinavir/r-Based Second-Line
Antiretroviral Therapy in Treatment-Experienced HIV Patients.
Han Y, Li Y, Xie J, er al
PLoS One. 2015 Mar 30;10(3):e0120705.
Paper
Is Zidovudine 1st line therapy virologically
comparable to Tenofovir in resource-limited settings?
Labhardt ND, Bader J, Lejone TI, et al
Trop Med Int Health.
2015 Mar 1
Abstract
FULL-TEXT
ARTICLE
The Impact of Choice of NNRTI on Short-Term Treatment Outcomes
among HIV-Infected Patients Prescribed Tenofovir and Lamivudine in
Johannesburg, South Africa.
Shearer K, Fox MP, Maskew M, et al
PLoS One.
2013 Aug 7;8(8):e71719.
Paper
FULL-TEXT PDF
ARTICLE
Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted
protease inhibitor-based regimen on renal function in HIV-infected
individuals: a prospective, multicenter study.
Cao Y, Han Y, Xie J, et
al
BMC Infect Dis.
2013 Jul 1;13(1):301.
Paper |
Tenofovir use and urinary biomarkers among
HIV-infected women in the Women's Interagency HIV Study (WIHS).
Oboho I, Abraham A, Benning L,
et a;
J Acquir Immune Defic Syndr.
2012 Dec 18.
Abstract
Efficacy and tolerance of
tenofovir-lamivudine-efavirenz combination in HIV-1 patients in
Fann Teaching Hospital in Dakar.]
Diop SA,
Fortes-Déguénonvo L, Seydi M, et al
Bull Soc Pathol Exot. 2012
Dec 17.
Abstract
Effectiveness and safety of a single-tablet regimen
of emtricitabine/efavirenz/tenofovir in HIV-1-infected patients in
infectious diseases department.
Xerinda
S, Neves N, Santos S, et al
J Int AIDS Soc. 2012 Nov
11;15(6):18383
Abstract
Safety and efficacy of once-daily single generic
fixed-drug combination tablet of tenofovir, lamivudine and
efavirenz among HIV-infected Thais.
Maek-A-Nantawat W, Avihingsanon A, Thainsanguankul W, et al
J Int AIDS Soc.
2012 Nov 11;15(6):18285.
Abstract
Tenofovir in second-line ART in Zambia and South
Africa: Collaborative analysis of cohort studies.
Wandeler G, Keiser O,
Mulenga L, et al
J Acquir Immune Defic Syndr.
2012 Jun 27.
Abstract
Where rilpivirine meets with tenofovir, the start of a
new anti-HIV drug combination era.
De Clercq E.
Biochem Pharmacol.
2012 Apr 5.
Abstract
FULL-TEXT
ARTICLE
Comparison of Bone and Renal Effects In HIV-infected Adults Switching to
Abacavir or Tenofovir Based Therapy
in a Randomized Trial.
Rasmussen TA, Jensen D, Tolstrup M,
et al
PLoS One.
2012;7(3):e32445.
Paper |
A Review of the Virological Efficacy of the 4 World Health
Organization-Recommended Tenofovir-Containing
Regimens for Initial HIV Therapy.
Tang MW, Kanki PJ,
Shafer RW.
Clin Infect Dis.
2012 Mar;54(6):862-75.
Abstract |
A Randomized Study of Tenofovir Disoproxil Fumarate in Treatment-Experienced
Human Immunodeficiency Virus-1 Infected Adolescents.
Negra MD, de Carvalho AP, de Aquino
MZ, et al
Pediatr Infect Dis J.
2012 Feb 1.
Abstract |
Topical Tenofovir, a Microbicide Effective against HIV,
Inhibits Herpes Simplex Virus-2 Replication.
Andrei G, Lisco A, Vanpouille C, et al
Cell Host Microbe.
2011 Oct 4;10(4):379-89.
Abstract |
Comparative outcomes of tenofovir- and zidovudine-based
antiretroviral therapy regimens in Lusaka, Zambia.
Moyo C, Schuttner L,
Mulenga LB,
et al
J Acquir Immune Defic Syndr. 2011 Aug
18
Abstract
Treatment Durability, Effectiveness, and Safety with Atazanavir/Ritonavir-Based
HAART Regimen
in Treatment-Naïve HIV-lnfected Patients.
Tremblay C, Trottier B, Rachlis A,
et al
HIV Clin Trials. 2011
May-Jun;12(3):151-60
Abstract
Long-Term Renal Safety of Tenofovir Disoproxil Fumarate in Vertically
HIV-Infected Children, Adolescents
and Young Adults: A 60-Month Follow-Up
Study.
Viganò A, Bedogni G,
Manfredini V, et
al
Clin Drug Investig. 2011;31(6):407-15
Abstract
Lipid-lowering effect of tenofovir in HIV-infected
patients.
Fabbiani M, Bracciale L, Doino M, et al
J Antimicrob Chemother.
2010 Dec 5
Abstract |
Comparison of Antiviral Activity of Regimens Containing
Nucleos(t)ide (NUC) Pairs in HIV-Infected Patients
Initiating REScue
Therapy (The NUCREST Study).|
Pérez-Molina JA, Serrano O, Milinkovic A, et al
HIV Clin Trials.
2010 Sep-Oct;11(5):294-302.
Abstract |
A pilot study to determine the impact on dyslipidemia of adding
tenofovir to stable
background antiretroviral therapy: ACTG 5206.
Tungsiripat
M, Kitch D, Glesby MJ, et al
AIDS.
2010 Jul 17;24(11):1781-4.
Abstract |
Lower arterial stiffness and Framingham score after
switching abacavir to tenofovir in men
at high cardiovascular risk.
Sinn K,
Richardson R, Carr A.
AIDS.
2010 Jul 19
Abstract |
Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy
compared
with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week
ARTEMIS data.
Nelson M, Girard PM, Demasi R,
et al
J Antimicrob Chemother.
2010 May 24
Abstract |
A Randomized Comparative Trial of Continued Zidovudine/Lamivudine or
Replacement With
Tenofovir Disoproxil Fumarate/Emtricitabine in Efavirenz-Treated
HIV-1-Infected Individuals.
Fisher M, Moyle GJ, Shahmanesh M et
al
J Acquir Immune Defic Syndr.
2009 Jun 25
Abstract |
Renal Function in Patients with Preexisting Renal Disease Receiving
Tenofovir-Containing Highly Active Antiretroviral Therapy in the HIV Outpatient
Study.
Young B, Buchacz K, Moorman A,
et al
AIDS Patient Care STDS.
2009 Jul 10.
Abstract |
The triple combination of tenofovir, emtricitabine and efavirenz shows
synergistic anti-HIV-1
activity in vitro: a mechanism of action study.
Feng JY, Ly JK, Myrick F, Goodman D, et al
Retrovirology.
2009 May 13;6(1):44
Abstract
|
A randomized trial of two-drug versus three-drug tenofovir-containing
maintenance regimens in virologically controlled HIV-1 patients.
Girard PM, Cabié A, Michelet C, et al
J Antimicrob Chemother. 2009 Apr 29
Abstract |
High rate of early virological failure with the once-daily
tenofovir/lamivudine/nevirapine combination
in naive HIV-1-infected patients.
Rey D, Hoen B, Chavanet P,
et al
J Antimicrob Chemother.
2008 Nov 2
Abstract |
| |
|
| |
Journal Main Page
Main
New/Newsworthy
